Workflow
Cardamyst
icon
Search documents
Milestone Pharmaceuticals Announces FDA Acceptance of the Company’s Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray
Globenewswire· 2025-07-11 10:00
New PDUFA Action Date of December 13, 2025 $75 Million Royalty Purchase Agreement Payment from RTW Extended Through 2025 MONTREAL and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) (Milestone) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Milestone’s response to issues raised in the Complete Response Letter (CRL) for CARDAMYST™ (etripamil) nasal spray, an investigational, novel therapy for the treatment of patients ...
Watch Milestone Pharmaceuticals For (Likely) Upcoming FDA Approval For Cardamyst
Seeking Alpha· 2025-07-07 14:01
Milestone Pharmaceuticals Inc. (NASDAQ: MIST ) is a microcap biotech company that was founded in 2003. It is based in Montreal, but also has a subsidiary in Charlotte, NC, with 30+ employees split fairly evenly between the two locations. Milestone IPO’d inI have been investing in the stock market since I was 17 years old, and over the 25+ years since I have learned the joy of compounding, the value of dividend reinvesting, and the principle that patient investing through good times and bad brings the greate ...